• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Wilex AG - Product Pipeline Review - 2012 Product Image

Wilex AG - Product Pipeline Review - 2012

  • ID: 2136020
  • May 2012
  • 80 pages
  • Global Markets Direct

Wilex AG – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Wilex AG - Product Pipeline Review - 2012” provides data on the Wilex AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Wilex AG’s corporate website, SEC filings, investor presentations and featured press releases, both from Wilex AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Wilex AG - Brief Wilex AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Wilex AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles READ MORE >



List of Tables
List of Figures
Wilex AG Snapshot
Wilex AG Overview
Key Information
Key Facts
Wilex AG – Research and Development Overview
Key Therapeutic Areas
Wilex AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Wilex AG – Pipeline Products Glance
Wilex AG – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Wilex AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Wilex AG – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Wilex AG – Drug Profiles
Antibody 1
Product Description
Mechanism of Action
R&D Progress
Antibody-Drug Conjugate
Product Description
Mechanism of Action
R&D Progress
MESUPRON + Gemzar
Product Description
Mechanism of Action
R&D Progress
MESUPRON + Xeloda
Product Description
Mechanism of Action
R&D Progress
Rencarex
Product Description
Mechanism of Action
R&D Progress
WX-037
Product Description
Mechanism of Action
R&D Progress
WX-554
Product Description
Mechanism of Action
R&D Progress
WX-UK1
Product Description
Mechanism of Action
R&D Progress
WX-UK1 + Xeloda
Product Description
Mechanism of Action
R&D Progress
Wilex AG – Pipeline Analysis
Wilex AG – Pipeline Products by Therapeutic Class
Wilex AG – Pipeline Products By Target
Wilex AG – Pipeline Products by Route of Administration
Wilex AG – Pipeline Products By Mechanism of Action
Wilex AG – Recent Pipeline Updates
Wilex AG - Dormant Projects
Wilex AG – Company Statement
Wilex AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Wilex AG, Recent Developments
Wilex AG- Press Release
Apr 11, 2012: WILEX Starts First Patient Study With MEK Inhibitor WX-554
Feb 27, 2012: FDA Approves Protocol Amendment For Final Analysis Of Pivotal RENCAREX Phase III Trial
Feb 06, 2012: WILEX Receives Funding From German Federal Ministry Of Education And Research For Development Of WX-037 As Part Of m4 Cluster Initiative
Jan 18, 2012: WILEX Successfully Completes Phase I Study In Healthy Volunteers With Oral MEK Inhibitor WX-554
Oct 02, 2009: WILEX Receives Approval For Phase I Trial With MEK Inhibitor WX-554
Sep 29, 2009: Mesupron In Combination With Gemcitabine Shows Clear Improvement In Tumour Response As Well As Median Survival And One Year Survival
Aug 04, 2009: WILEX Files Application For Approval Of Phase I Trial For WX-554 And Thereby Achieves First Milestone Of The Strategic Aalliance With UCB
Jan 09, 2009: UCB And WILEX Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
Jan 09, 2009: UCB And WILEX Enter Into Strategic Alliance To Develop UCB's Preclinical Oncology Portfolio
Financial Deals Landscape
Wilex AG, Deals Summary
Wilex AG, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
WILEX To Acquire Oncogene Science Assets From Siemens Healthcare Diagnostics
Wilex Acquires Intellectual Property From Dendreon
Venture Financing
Heidelberg Pharma Raises $20.3 Million In Series B Financing
Wilex Secures $39 Million In Series C Financing Round
Heidelberg Pharma Secures $31 Million In The Second Round Of Venture Financing
Partnerships
WILEX Enters Into Licensing Agreement With Ion Beam Applications
WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
WILEX Enters Into An Agreement With IBA Molecular
Heidelberg Pharma Enters Into Co-Development Agreement With Galilaeus For Cancer Drugs
Wilex Enters Into Co-Development Agreement With Esteve
Licensing Agreements
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX
UCB Enters Into Licensing Agreement With WILEX
Equity Offering
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million
WILEX Completes Rights Issue Of Common Stock For $13.4 Million
WILEX Completes IPO Of $80 Million
Acquisition
WILEX Acquires Heidelberg Pharma For $26.8 Million
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX
UCB Pharma Acquires An Additional 6.65% Stake In WILEX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Wilex AG, Key Information
Wilex AG, Key Facts
Wilex AG – Pipeline by Indication, 2012
Wilex AG – Pipeline by Stage of Development, 2012
Wilex AG – Monotherapy Products in Pipeline, 2012
Wilex AG – Combination Treatment Modalities in Pipeline, 2012
Wilex AG – Phase III, 2012
Wilex AG – Phase II, 2012
Wilex AG – Phase I, 2012
Wilex AG – Pre-Clinical, 2012
Wilex AG – Pipeline By Therapeutic Class, 2012
Wilex AG - Pipeline By Target, 2012
Wilex AG – Pipeline By Route of Administration, 2012
Wilex AG – Pipeline Products By Mechanism of Action, 2012
Wilex AG – Recent Pipeline Updates, 2012
Wilex AG - Dormant Developmental Projects,2012
Wilex AG, Subsidiaries
Wilex AG, Deals Summary
WILEX To Acquire Oncogene Science Assets From Siemens Healthcare Diagnostics
Wilex Acquires Intellectual Property From Dendreon
Heidelberg Pharma Raises $20.3 Million In Series B Financing
Wilex Secures $39 Million In Series C Financing Round
Heidelberg Pharma Secures $31 Million In The Second Round Of Venture Financing
WILEX Enters Into Licensing Agreement With Ion Beam Applications
WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
WILEX Enters Into An Agreement With IBA Molecular
Heidelberg Pharma Enters Into Co-Development Agreement With Galilaeus For Cancer Drugs
Wilex Enters Into Co-Development Agreement With Esteve
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX
UCB Enters Into Licensing Agreement With WILEX
WILEX Enters Into Standby Equity Distribution Agreement For $27 Million
WILEX Completes Rights Issue Of Common Stock For $13.4 Million
WILEX Completes IPO Of $80 Million
WILEX Acquires Heidelberg Pharma For $26.8 Million
dievini Hopp BioTech Holding Acquires 0.12% Stake In WILEX
UCB Pharma Acquires An Additional 6.65% Stake In WILEX

List of Figures
Wilex AG – Pipeline by Indication, 2012
Wilex AG – Pipeline by Stage of Development, 2012
Wilex AG – Monotherapy Products in Pipeline, 2012
Wilex AG – Combination Treatment Modalities in Pipeline, 2012
Wilex AG – Pipeline By Therapeutic Class, 2012
Wilex AG - Pipeline By Target, 2012
Wilex AG – Pipeline By Route of Administration, 2012
Wilex AG - Pipeline Products By Mechanism of Action, 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos